Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors

23 kwietnia 2026 zaktualizowane przez: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety, Anti-tumor Activity, Pharmacokinetic/Pharmacodynamic Characteristics of FXB0871 as Monotherapy in Participants With Selected Locally Advanced or Metastatic Solid Tumors

This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with selected locally advanced or metastatic solid tumors. In Part Ia, participants with selected solid tumors that have progressed after, are intolerant to, or are not suitable for standard therapy will receive FXB0871 in dose-escalation cohorts to determine the maximum tolerated dose and/or recommended phase 2 dose. In Part Ib, participants with PD-(L)1-resistant non-small cell lung cancer or hepatocellular carcinoma will receive FXB0871 in dose-expansion cohorts to further evaluate antitumor activity, safety, and dose optimization.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

This first-in-human study consists of a dose-escalation part (Part Ia) and a dose-expansion part (Part Ib). In Part Ia, adults with selected locally advanced or metastatic solid tumors will receive FXB0871 monotherapy by intravenous infusion every 2 weeks in sequential pre-determinde dose cohorts using a Bayesian optimal interval design. The planned dosing schedule is every 2 weeks, with a dose-limiting toxicity observation period of the first 2 treatment cycles. Additional intermediate dose levels, cohort expansion, and schedule optimization to every 3 or 4 weeks may be allowed according to protocol-defined safety, PK/PD, and preliminary antitumor activity data.

Part Ib will start after determination of the monotherapy recommended phase 2 dose (RP2D). Cohort A will enroll participants with PD-(L)1-resistant locally advanced or metastatic non-small cell lung cancer and randomize them 1:1 to receive FXB0871 at the RP2D or at a lower dose selected on the basis of Part Ia data. Cohort B will enroll participants with PD-(L)1-resistant locally advanced or metastatic hepatocellular carcinoma to receive FXB0871 at the RP2D. Participants may continue study treatment for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

138

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

  • Chiny
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chiny, 200000
        • Shanghai East Hospital
        • Kontakt:
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Signed informed consent.
  • Age ≥18 years.
  • Histologically confirmed selected locally advanced or metastatic solid tumor with progression on, intolerance to, or no suitable standard therapy.
  • ECOG performance status 0 or 1.
  • At least one measurable lesion per RECIST v1.1.
  • Pretreatment tumor tissue available (archival or fresh biopsy).
  • Life expectancy ≥12 weeks.
  • Oxygen saturation ≥92% on room air.
  • Left ventricular ejection fraction >50%.
  • Adequate hematologic, coagulation, renal, hepatic, and cardiac function.
  • Women of childbearing potential and sexually active men must use highly effective contraception.
  • Tumor-specific eligibility applies, including prior anti-PD-(L)1 treatment failure for the selected cohorts.

Key Exclusion Criteria:

  • Systemic anti-cancer therapy, major surgery, or radical radiotherapy within 4 weeks before first dose.
  • Prior treatment with IL-2, IL-15, or IL-7.
  • Active autoimmune disease requiring systemic treatment or immunodeficiency.
  • Systemic corticosteroids (≥10 mg/day prednisone equivalent) or other immunosuppressive therapy within 28 days before first dose, with limited protocol-defined exceptions.
  • Active or untreated central nervous system metastases, carcinomatous meningitis, or leptomeningeal disease.
  • Uncontrolled infection or clinically significant unresolved toxicities from prior therapy.
  • Clinically significant cardiovascular/cerebrovascular disease, uncontrolled effusions/ascites, uncontrolled hypertension, or QTcF >470 ms.
  • Active hepatitis B/C, syphilis, or HIV infection.
  • Clinically significant interstitial lung disease or active noninfectious pneumonitis.
  • Pregnancy or breastfeeding.
  • Any other serious medical or psychiatric condition that, in the investigator's judgment, would make participation inappropriate.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Arm1：Part Ia Dose Escalation
Participants with selected locally advanced or metastatic solid tumors will receive FXB0871 monotherapy by intravenous infusion every 2 weeks in sequential pre-determined dose-escalation cohorts or at intermediate dose levels every 2 weeks
Biologiczny: Intervention1：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Part Ia every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Inne nazwy:
  • TEV-56278
Eksperymentalny: Arm2：Part Ib Dose Expansion (NSCLC, RP2D)
Participants with locally advanced or metastatic IO-resistant NSCLC will be randomized 1:1 to receive FXB0871 monotherapy at RP2D from Phase Ia by intravenous infusion every 2 weeks
Biologiczny: Intervention2：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Inne nazwy:
  • TEV-56278
Eksperymentalny: Arm3：Part Ib Dose Expansion(NSCLC, <RP2D)
Participants with locally advanced or metastatic IO-resistant NSCLC will be randomized 1:1 to receive FXB0871 monotherapy at a selected lower dose than RP2D from Phase Ia by intravenous infusion every 2 weeks
Biologiczny: Intervention3：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Inne nazwy:
  • TEV-56278
Eksperymentalny: Arm4：Part Ib Dose Expansion(HCC, RP2D)
Participants with locally advanced or metastatic IO-resistant HCC will receive FXB0871 monotherapy at RP2D from Phase Ia by intravenous infusion every 2 weeks
Biologiczny: Intervention4：FXB0871
FXB0871 is administered by intravenous infusion at pre-determined dose level in Phase Ib every 2 weeks. Treatment may continue for up to 12 months or until unacceptable toxicity, disease progression, or another protocol-defined discontinuation criterion is met.
Inne nazwy:
  • TEV-56278

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Incidence and severity of dose-limiting toxicities (DLTs) in Phase Ia
Ramy czasowe: First 2 cycles after first dose (each cycle = 14 days; approximately 28 days).
Percentage of participants with protocol-defined DLTs during the DLT observation period in the dose-escalation phase
First 2 cycles after first dose (each cycle = 14 days; approximately 28 days).
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose delay/interruption/reduction/treatment discontinuation in Phase Ia
Ramy czasowe: From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first
Safety assessed by the incidence of treatment-emergent adverse events, serious adverse events, AEs leading to dose delay/interruption/reduction/treatment discontinuation in Phase Ia.
From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first
Objective response rate (ORR) in Phase Ib
Ramy czasowe: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).
ORR defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 in Phase Ib.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Objective response rate (ORR) in Phase Ia
Ramy czasowe: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Objective response rate (ORR), defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed per RECIST v1.1 in Phase Ia.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Disease control rate (DCR) in Phase Ia
Ramy czasowe: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Disease control rate (DCR), defined as the proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed per RECIST v1.1 in Phase Ia.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Duration of response (DOR) in Phase Ia
Ramy czasowe: From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Duration of response (DOR), defined for participants with confirmed CR or PR as the time from first documented response to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ia.
From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Progression-free survival (PFS) in Phase Ia
Ramy czasowe: From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Progression-free survival (PFS), defined as the time from first dose to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ia.
From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Peak serum concentration (Cmax)
Ramy czasowe: Predose up to Day 8
Maximum observed concentration
Predose up to Day 8
Time to maximum observed concentration (Tmax)
Ramy czasowe: Predose up to Day 8
Time to maximum observed drug concentration
Predose up to Day 8
Area under the serum concentration-time curve (AUC0-last)
Ramy czasowe: Predose up to Day 8
Area under the serum concentration-time curve from time 0 to last measurable drug concentration
Predose up to Day 8
Area under the serum concentration-time curve (AUC0-∞)
Ramy czasowe: Predose up to Day 8
Area under the concentration-time curve from time zero (pre-dose) extrapolation to infinite time
Predose up to Day 8
Area under the serum concentration-time curve (AUCtau)
Ramy czasowe: Predose up to Day 8
Area under the concentration-time curve over the dosing interval
Predose up to Day 8
Trough concentration (Ctrough)
Ramy czasowe: up to Day 8
Observed concentration at the end of a dosing interval, immediately before next administration
up to Day 8
Clearance (CL)
Ramy czasowe: Predose up to Day 8
Systemic (total body) clearance following iv administration
Predose up to Day 8
Volume of distribution (Vz)
Ramy czasowe: Predose up to Day 8
Volume of distribution following iv administration
Predose up to Day 8
Half-life (t1/2)
Ramy czasowe: Predose up to Day 8
Terminal phase half-life
Predose up to Day 8
Average concentration (Cavg)
Ramy czasowe: Predose up to Day 8
Average concentration over a dosing interval
Predose up to Day 8
Accumulation ratio (Rac)
Ramy czasowe: Predose up to Day 8
Accumulation ratio
Predose up to Day 8
Incidence and severity of AEs/SAEs and AEs leading to dose modification or discontinuation in Phase Ib
Ramy czasowe: From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first.
Safety and tolerability in the dose-expansion phase.
From first dose through 90 days after last dose or initiation of new anti-tumor therapy, whichever occurs first.
ORR by modified RECIST (mRECIST) in the HCC cohort of Phase Ib
Ramy czasowe: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).
ORR in participants with hepatocellular carcinoma assessed by mRECIST.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study (assessed every 8±1 weeks; approximately up to 24 months).
Disease control rate (DCR) in Phase Ib
Ramy czasowe: From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Disease control rate (DCR), defined as the proportion of participants with a best overall response of CR, PR, or SD, as assessed per RECIST v1.1 in Phase Ib.
From first dose until disease progression, start of new anti-tumor therapy, withdrawal, death, or end of study, whichever occurs first (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Time to response (TTR) in Phase Ib
Ramy czasowe: From first dose to first documented CR or PR (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Time to response (TTR), defined as the time from first dose to the first documented CR or PR, as assessed per RECIST v1.1 in Phase Ib.
From first dose to first documented CR or PR (tumor assessments every 8 ± 1 weeks; approximately up to 24 months).
Duration of response (DOR) in Phase Ib
Ramy czasowe: From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Duration of response (DOR), defined for participants with confirmed CR or PR as the time from first documented response to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ib.
From first documented CR or PR until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Title:Progression-free survival (PFS) in Phase Ib
Ramy czasowe: From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Progression-free survival (PFS), defined as the time from first dose to first documented disease progression or death from any cause, whichever occurs first, as assessed per RECIST v1.1 in Phase Ib.
From first dose until first documented disease progression or death from any cause, whichever occurs first (approximately up to 24 months).
Overall survival (OS) in Phase Ib
Ramy czasowe: From first dose until death from any cause (approximately up to 24 months).
Overall survival measured from first dose to death from any cause.
From first dose until death from any cause (approximately up to 24 months).

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 maja 2026

Zakończenie podstawowe (Szacowany)

23 kwietnia 2030

Ukończenie studiów (Szacowany)

18 listopada 2030

Daty rejestracji na studia

Pierwszy przesłany

7 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

23 kwietnia 2026

Pierwszy wysłany (Rzeczywisty)

30 kwietnia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

30 kwietnia 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

23 kwietnia 2026

Ostatnia weryfikacja

1 kwietnia 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • FXB0871-I101

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Rak wątrobowokomórkowy

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Tunisia

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj